Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 2131 to 2145 of 8984 results

  1. Semaglutide for treating moderate to advanced liver fibrosis (without cirrhosis) caused by metabolic dysfunction-associated steatohepatitis [ID6458]

    In development Reference number: GID-TA11477 Expected publication date: TBC

    Technology appraisal guidance
    In development

  2. Cabozantinib for treating advanced neuroendocrine tumours that have progressed after systemic treatment [ID6474]: final draft guidance

    We are listening to your views on this Technology appraisal guidance. Comments close 30 April 2026.

    Technology appraisal guidance
    In consultation

  3. Tislelizumab with chemotherapy for untreated recurrent or metastatic nasopharyngeal cancer [ID6304]: consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators

    We are listening to your views on this Technology appraisal guidance. Comments close 28 April 2026.

    Technology appraisal guidance
    In consultation

  4. Reinforcement of a permanent stoma with synthetic or biological mesh to prevent a parastomal hernia

    Awaiting development Reference number: GID-HTG10678 Expected publication date: TBC

    HealthTech guidance
    Awaiting development

  5. Tislelizumab with chemotherapy for untreated recurrent or metastatic nasopharyngeal cancer [ID6304]

    In development Reference number: GID-TA11100 Expected publication date: TBC

    Technology appraisal guidance
    In development

  6. Treprostinil diethanolamine for treating pulmonary arterial hypertension [ID6366]

    Awaiting development Reference number: GID-TA11123 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  7. Head injury (QS74) update: topic engagement

    We are listening to your views on this Quality standard. Comments close 30 April 2026.

    Quality standard
    In consultation

  8. Tiragolumab–atezolizumab for PD-L1-positive recurrent or advanced non-small-cell lung cancer untreated with checkpoint inhibitors [TSID12064]

    Awaiting development Reference number: GID-TA11594 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  9. Retifanlimab with chemotherapy for previously untreated metastatic non-small-cell lung cancer [ID6436]

    Awaiting development Reference number: GID-TA11532 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  10. Cositecan for treating platinum or taxane resistant advanced, mucinous, epithelial ovarian cancer [ID826]

    In development Reference number: GID-TA10446 Expected publication date: TBC

    Technology appraisal guidance
    In development

  11. Lurbinectedin for treating advanced platinum-resistant ovarian cancer [ID1340]

    In development Reference number: GID-TA10313 Expected publication date: TBC

    Technology appraisal guidance
    In development

  12. Subcutaneous amivantamab for treating advanced non-small-cell lung cancer with EGFR mutations [TSID12011]

    Topic prioritisation

    Technology appraisal guidance
    Topic prioritisation

  13. Advanced breast cancer: diagnosis and management (Partial update)

    In development Reference number: GID-NG10430 Expected publication date:  05 June 2026

    NICE guideline
    In development

  14. Datopotamab deruxtecan with durvalumab for treating triple-negative breast cancer when there is residual invasive disease after neoadjuvant systemic treatment and surgery [ID6643]

    Awaiting development Reference number: GID-TA11835 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  15. Elranatamab for treating relapsed and refractory multiple myeloma after 3 or more treatments (managed access review of TA1023) [ID6653]

    Awaiting development Reference number: GID-TA11956 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development